報價延遲最少15分鐘:2025/08/23 02:30 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.8 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.85/0.88
|
|
企業價值
4.16B
|
| 資產負債 |
|
每股賬面淨值
1.67
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
426.45M
|
|
每股收益
0.87
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/23 02:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and othersat risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions tocertain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
